Lundbeck partners with AI firm Cradle for antibody development in neurological disorders
By
Rowan Walrath
Summary
Danish pharmaceutical company Lundbeck has partnered with AI firm Cradle to use its artificial intelligence software for designing two antibodies targeting neurological disorders. The collaboration leverages Cradle's AI capabilities to accelerate antibody development in the neurology space.
Source
bskyLundbeck partners with AI firm Cradle for antibody development in neurological disorderscen.acs.orgKey quotes
· 2 pulledThe Danish pharmaceutical company Lundbeck has tapped the artificial intelligence firm Cradle to help develop two antibodies to treat neurological disorders.
Lundbeck scientists will use Cradle's artificial intelligence software for 2 programs
You might also wanna read
British startup sends biology lab to orbit to gather microgravity protein data for AI models targeting Alzheimer's and cancer
A British startup has launched a biology laboratory into low-Earth orbit to collect microgravity protein data and transmit it back to Earth.
noncemedia.com·11h ago
Alp Bio's AI platform predicts immune reactions to biologic drugs in early development
An interview with Christian Vahlensieck, co-founder of Alp Bio, a Swiss startup using an AI-powered platform combined with lab-grown human i
Alp Bio's AI platform predicts immune reactions to biologic drugs earlier in development
An interview with Christian Vahlensieck, co-founder of Alp Bio, a Swiss startup using an AI-powered platform combined with lab-grown human i
NVIDIA and LG Group Partner to Build AI Factory for Robotics, Autonomous Driving, and Cloud Infrastructure
NVIDIA and LG Group are collaborating to build an AI factory that will provide accelerated computing infrastructure for LG's AI-driven busin
Spine Platform: A New Agentic System for Coordinated Human-AI Collaboration
Spine is a new agentic platform designed to revolutionize human-AI collaboration by creating a swarm of specialized AI agents that work toge
getspine.ai·3mo ago
AI-Driven Protein Binder Design: Progress and Pitfalls in Evaluation Practices
This article discusses the rapid advancement of de novo protein binder design using AI, including antibodies and nanobodies. While the field
boltz.bio·8d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.